Key Highlights

  • New CSO Named: Björn Tackenberg, M.D., Ph.D., FEAN, FAAN, a Professor of Neurology and former Roche executive, joins Oculis as Chief Scientific Officer.
  • Privosegtor Focus: Prof. Tackenberg's immediate priorities include advancing Privosegtor through the PIONEER registrational program and evaluating its potential in acute MS relapses.
  • Complementary VP Appointment: Aaron Tansy, M.D., joins as Vice President, Development Franchise Head, Neurology, adding expertise in global clinical development.
  • Neurology Expansion: The appointments signal Oculis' strategic intent to extend its lead asset beyond its original indications into broader neurological applications.

Oculis Holding AG(NASDAQ:OCS), a global biopharmaceutical company based in Zug, Switzerland, announced on November 2, 2026 that it has appointed Björn Tackenberg, M.D., Ph.D., FEAN, FAAN as its new Chief Scientific Officer. The appointment marks a significant addition to Oculis' Leadership team as the company advances its lead asset, Privosegtor, through a registrational clinical program and evaluates its potential in neurological indications beyond ophthalmology.

A CSO With Deep Neuroimmunology Credentials

Prof. Tackenberg brings a career that spans academic neurology, pharmaceutical development, and medical affairs leadership. He joins Oculis from Roche, where he served as Head of Integrative Neuroscience and Medical Practice, overseeing clinical development plans, biomarker development strategies, and partnerships with scientific institutions.

Before his time at Roche, Prof. Tackenberg spent more than a decade at Marburg University in Germany, where he served as Head of the Center of Neuroimmunology and Vice-Chair of the Department of Neurology. During that period, he established a Clinical Trials unit that conducted more than 75 randomized controlled trials in autoimmune indications. His academic and industry background spans multiple sclerosis, neurodegenerative diseases, neuromuscular diseases, and inflammatory neuropathies.

He is board-certified as a neurologist and has authored or co-authored more than 135 original publications. His credentials include fellowship status in both the European Academy of Neurology and the American Academy of Neurology — distinctions that reflect recognition by leading specialty organizations on both sides of the Atlantic.

What This Means for Privosegtor and the PIONEER Program

Privosegtor is Oculis' lead therapeutic candidate, currently advancing through the PIONEER registrational program. In his new role, Prof. Tackenberg will lead Oculis' global integrated scientific strategy, direct research portfolio development, and oversee the evaluation of Privosegtor's therapeutic potential in neurological indications beyond its current focus.

One of the most notable areas of evaluation disclosed in the announcement is the potential application of Privosegtor in acute multiple sclerosis relapses. MS is a chronic autoimmune neurological disease affecting millions of people worldwide, and acute relapses represent a specific clinical setting where new treatments have historically been limited. The disclosure that Oculis is evaluating Privosegtor in this context signals a potentially significant expansion of the asset's commercial opportunity beyond its original indications.

Alongside Prof. Tackenberg, Oculis has appointed Aaron Tansy, M.D., as Vice President, Development Franchise Head, Neurology. Dr. Tansy brings complementary expertise in neurology and global clinical development, and his appointment alongside the new CSO suggests the company is building out a dedicated neurology team to support this expansion.

Risks

Oculis remains a clinical-stage company, and Privosegtor has not yet received regulatory approval for any indication. The PIONEER registrational program must successfully demonstrate efficacy and safety to the satisfaction of regulatory authorities, and the outcome of any registrational trial carries inherent uncertainty.

Expanding a drug candidate into new neurological indications such as MS relapses requires additional clinical data. Even if Privosegtor succeeds in its current registrational program, there is no guarantee that its mechanism will produce meaningful results in MS or other neurological indications. Building a neurology franchise alongside an existing neuro-ophthalmology program also requires substantial operational and financial resources.

What to Watch Next

Progress updates from the PIONEER registrational program will be the most closely tracked milestones. Any data readouts from the program, enrollment updates, or changes to the clinical timeline will provide insight into how Privosegtor is performing in the registrational setting.

Prof. Tackenberg's disclosed evaluation of Privosegtor in MS relapses is also worth watching. Any decision to initiate a formal clinical study in that indication would be a notable pipeline expansion event.

Sector Context

Neuro-ophthalmology occupies an intersection between neurology and ophthalmology, addressing conditions where the visual system is affected by neurological disease processes. This convergence has created commercial opportunities for biopharmaceutical companies able to develop drugs that address neurological pathways with ophthalmic manifestations.

The addition of leadership from the broader neurology field — particularly someone with Prof. Tackenberg's depth in autoimmune neurology — suggests that Oculis sees its scientific platform as potentially extendable beyond the eye into the broader central nervous system.